Related Experiment Video
Updated: Feb 10, 2026

In Vitro Analysis of E3 Ubiquitin Ligase Function
Published on: May 14, 2021
OSTM1 is a ubiquitin E3 ligase that suppresses B-cell malignancy by activating the cAMP/PKA/CREB pathway
Abstract:
Osteoclastogenesis-associated transmembrane protein 1 (OSTM1) is a membrane-integral glycosylated protein known for regulating lysosomal homeostasis, with loss-of-function mutations causing autosomal recessive osteopetrosis. Through a whole-genome CRISPR/Cas9 screen, we identified OSTM1 as a critical tumor suppressor in B-cell malignancies. In humans, OSTM1 is frequently deleted or downregulated across a wide range of B-cell malignancies. In mice, B-cell-specific monoallelic or biallelic Ostm1 ablation cooperates with Cdkn2a loss to drive lymphomagenesis with near 100% penetrance. Mechanistically, we reveal that a cytosolic, non-glycosylated fraction of OSTM1 functions as an E3 ligase that targets phosphodiesterase 3B (PDE3B) for proteasomal degradation. Because PDE3B catalyzes the conversion of cAMP to AMP and thereby negatively regulating the cAMP-dependent PKA/CREB/CREBBP tumor suppressive pathway, the loss of OSTM1 leads to PDE3B stabilization and enhanced cell transformation. Our findings establish OSTM1 as a pivotal E3 ligase that prevents B-cell lymphomagenesis through the regulation of the cAMP/PKA/CREB pathway.
Insights
Osteoclastogenesis-associated transmembrane protein 1 (OSTM1) acts as a tumor suppressor in B-cell cancers. Loss of OSTM1 function stabilizes PDE3B, promoting cancer cell growth by disrupting the cAMP pathway.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Osteoclastogenesis-associated transmembrane protein 1 (OSTM1) is crucial for lysosomal homeostasis and its mutations cause osteopetrosis.
- OSTM1's role in cancer, particularly B-cell malignancies, was previously unexplored.
Purpose of the Study:
- To investigate the role of OSTM1 in B-cell malignancies.
- To elucidate the molecular mechanisms by which OSTM1 suppresses tumors.
Main Methods:
- Whole-genome CRISPR/Cas9 screening in B-cell malignancies.
- Analysis of OSTM1 expression in human B-cell cancers.
- Ostm1 gene ablation in mice models.
- Biochemical assays to determine OSTM1's E3 ligase activity and substrate.
Main Results:
- OSTM1 functions as a critical tumor suppressor in B-cell malignancies, frequently deleted or downregulated in human cancers.
- Ostm1 deficiency in mice, alongside Cdkn2a loss, drives lymphomagenesis with high penetrance.
- OSTM1 acts as an E3 ligase targeting phosphodiesterase 3B (PDE3B) for degradation.
- Loss of OSTM1 leads to PDE3B stabilization, enhancing the cAMP/PKA/CREB/CREBBP tumor-promoting pathway.
Conclusions:
- OSTM1 is a key tumor suppressor in B-cell lymphomagenesis.
- OSTM1 prevents B-cell cancer by regulating the cAMP pathway via PDE3B degradation.
- OSTM1 represents a potential therapeutic target for B-cell malignancies.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Intracellular Signaling Cascades
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Endocrine Signaling

